Picture EBD Group Biotech Showcase 2024 San Francisco 650x100px
Document › Details

Consilium Strategic Communications Ltd.. (10/15/20). "Press Release: Consilium Strategic Communications Advises Compass Pathways on Its Successful Initial Public Offering". London.

Organisations Organisation Consilium Strategic Communications Ltd. (CSC)
  Today ICR Consilium Strategic Communications
  Group ICR (Group)
  Organisation 2 Compass Pathways plc (Nasdaq: CMPS)
  Group Compass Pathways (Group)
Products Product public relations / investor relations / marcom (services)
  Product 2 psilocybin
Index term Index term Compass Pathways–SEVERAL: investment, 202004 financing round Series B $80m from existing + new investors
Persons Person Fennell, Amber (Bielecka, Amber) (Consilium Strategic Communications 201307– Co-founder)
  Person 2 Gardner, Chris (Consilium 201507– Partner before since 2003 at Citigate Dewe Rogerson London)

Mental health care company raises $146.6 million on Nasdaq

Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to have advised on the successful initial public offering (IPO) of COMPASS Pathways (“COMPASS”) on Nasdaq. The offering raised $146.6 million. COMPASS began trading on the Nasdaq Global Select Market on September 18, 2020 under the ticker symbol “CMPS”. 

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. It is pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support from specially trained therapists. Its initial focus is on treatment-resistant depression, an area of significant unmet medical need.

The Consilium team was led by Amber Fennell and supported by Chris Gardner, David Daley, Alix Floyd, Olivia Manser, Lizzie Seeley and Maya Bennison. Consilium continues to advise the company on its financial communications as a publicly listed company. Cowen, Evercore ISI and Berenberg acted as Joint Global Coordinators and Joint Bookrunners in the offering.

Proceeds from the IPO will be used to fund clinical trials, therapist training and other activities to support the development of COMPASS’ investigational COMP360 psilocybin therapy; to fund research and clinical development activities to support the progression of the COMP360 psilocybin therapy for other neuropsychiatric indications; to fund general business development activities; and to fund general and administrative expenses, working capital and other general corporate purposes.

Commenting on COMPASS’ successful IPO, Amber Fennell, Partner and Co-Founder of Consilium Strategic Communications, said: “We are delighted to have supported COMPASS through this major milestone. The team at COMPASS have an impressive vision of a world of mental wellbeing which we are proud to help them communicate internationally. We look forward to supporting COMPASS as a listed company as it continues to transform mental health care.”

Consilium also advised on the communications surrounding the Nasdaq listing of Silence Therapeutics, a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, in September 2020. Silence Therapeutics is led by recently appointed President and CEO, Mark Rothera, based in US, and has commenced a search for a US based CFO as it strengthens its team and increases its visibility into the US.


For more information, please contact:

Consilium Strategic Communications
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700

Follow us: @consiliumhc

About Consilium Strategic Communications

Consilium Strategic Communications is a global leader in strategic healthcare communications and investor relations advisory with offices in Europe and across the US. Consilium's highly skilled team provides strategic, long-term advice to healthcare companies, Boards, senior decision makers and executives on critical communications and IR programmes and stakeholder challenges. The Company has established deep knowledge across all areas of the global healthcare sector through broad experience in representing international clients spanning the Fortune 500, FTSE100, FTSEurofirst 300 and FTSE250, through to discrete specialist reputation management projects.

About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing.

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for ICR (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Special Topic HealthCapital Berlin-Brandenburg 650x300px

» top